Floatz logo

Epoch-F/R

Non-Hodgkins Lymphoma

National Cancer Institute (NCI)Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Non-Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
Keyhole Limpet Hemocyanin
Biovest International
Phase 3B
Fnhlid1
Biovest International
Phase 3B
Campth-1H
SCRI Development Innovations, LLC
Phase 2B
IBRITUMOMAB TIUXETAN
SCRI Development Innovations, LLC
Phase 2CCC
APG 115
Ascentage Pharma Group Inc.
Phase 2CCC

View all 21 →

Same molecule, other indications

Epoch-F/R is also rated in:

Hodgkins LymphomaDormant
CC
Indicative ·
43 / 100
View asset →
MDSDormant
CC
Indicative ·
41 / 100
View asset →
LeukemiaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →